NC-SONION
Sonion, the global leader in micro acoustic and micro mechanical technologies and solutions for hearing instruments and specialty earphones, and Valencell, the leading innovator in wearable biometric sensor technology, today announced a strategic partnership that will expand the boundaries for the use of biometric sensors in the ear. In the partnership Valencell provides the industry’s most advanced biometric sensor modules for hearables and wearables, which Sonion will optimize for size, power consumption and cost for in-ear and on-ear applications. The partnership focuses on designing, developing and manufacturing biometric sensing ear modules for the medical, hearing health, consumer and professional communications markets.
The partnership leverages Valencell’s expertise and experience as a leader in wearable biometrics and Sonion’s more than 40 years of experience as a leader in the development and manufacturing of products for the hearing health market. Under the partnership, Sonion will introduce a wide range of sensor modules for different applications in the ear and Valencell will continue to further develop its innovative portfolio of advanced, accurate biometric sensor capabilities for all form factors. Sonion will also integrate its world class balanced armature speakers among other components as part of the sensor modules.
Sonion’s manufacturing expertise in miniaturized components for ear-based devices is expected to result in significant reductions to the size, cost and power consumption of photoplethysmography (PPG)-based sensors for continuous heart rate, blood pressure, and other medical monitoring and fitness/wellness related functionalities into hearables, hearing aids and other ear-level devices.
The markets for hearables and hearing health devices are both predicted to show a steady growth. The consumer hearables segment is expected to grow at 48% CAGR through 2022, according to IDC , while the hearing health market is expected to continue to demonstrate stable growth numbers and increase 22% over the same period according to OrbisResearch.com
In addition, as part of the partnership, Sonion has made a strategic investment of an undisclosed amount in Valencell, making Sonion a significant shareholder in Valencell Inc.
“I am truly excited about the partnership with Valencell,” says Jesper Ahlmann Funding Andersen, President & CEO of Sonion a/s. “We are bringing the best of two worlds together. Biometric sensing is the next big thing for many of our customers, making the ear-level devices truly multi-functional. Joining forces with the global leader in this field - Valencell - brings accuracy and the possibility to add innovative new metrics to the products we develop for our customers, including advanced medical monitoring. We look forward to together setting a new standard for what is possible.”
“This partnership with Sonion brings tremendous value to the hearables and hearing health markets, as well as to our current and future customers and partners,” said Michael Dering, CEO of Valencell. “Sonion brings world-class expertise and capabilities in hearing health component development, manufacturing, and distribution. As demonstrated by Valencell’s foundational patents in biometric hearables, since foundation we have envisioned a world where traditional ear-worn devices can be used to improve public health. Valencell and Sonion share a strong vision and operating model for making major advancements in hearing health and hearable devices. We are excited about the great things to come.”
About Sonion
Sonion a/s is a Novo Holding a/s owned global leader in microacoustics and micromechanics for hearing health and other ear-level devices. The company – which is headquartered in Roskilde, Denmark - employs over 5.500 employees across sites in Denmark, Holland, USA, China, Poland, Vietnam and Philippines.
About Valencell
Valencell produces the most accurate wearable biometric sensor systems in the world and provides this patent-protected technology to consumer electronics manufacturers, mobile device and accessory makers, medical device makers, sports and fitness brands and gaming companies for integration into their products. Protected by more than 60 granted patents and more than 100 patents pending, Valencell’s technology can be used in wearables and hearables for virtually anyone, anywhere, doing anything. Their technology is scalable to multiple form-factors such as earbuds, smartwatches, armbands and wrist devices and is currently integrated into more biometric wearable devices than any other technology provider in the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180606005468/en/
Contact:
Sonion Media Contact:
Merethe Svahn Hansen
mha@sonion.com
+45
5158 8906
or
Valencell Media Contact:
Ryan
Kraudel, VP Marketing at Valencell
Kraudel@valencell.com
919-747-3668x3050
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom